24 related articles for article (PubMed ID: 8797143)
1. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study.
Choi HK; Soriano LC; Zhang Y; RodrÃguez LA
BMJ; 2012 Jan; 344():d8190. PubMed ID: 22240117
[TBL] [Abstract][Full Text] [Related]
2. Irbesartan: a review of its use in hypertension and diabetic nephropathy.
Croom KF; Plosker GL
Drugs; 2008; 68(11):1543-69. PubMed ID: 18627212
[TBL] [Abstract][Full Text] [Related]
3. Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy.
Croom KF; Curran MP; Goa KL; Perry CM
Drugs; 2004; 64(9):999-1028. PubMed ID: 15101793
[TBL] [Abstract][Full Text] [Related]
4. Irbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension.
Gillis JC; Markham A
Drugs; 1997 Dec; 54(6):885-902. PubMed ID: 9421695
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the oral angiotensin II receptor antagonist UP 269-6 or enalapril 20 mg on blood pressure and neurohormonal effects in salt-deplete man.
McIntyre M; MacFadyen RJ; Meredith PA; Menard J; Brunner HR; Insuasty J; Reid JL
J Cardiovasc Pharmacol; 1995 Jun; 25(6):994-1000. PubMed ID: 7564347
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the acute effects of angiotensin II by the receptor antagonist irbesartan in normotensive men.
Ribstein J; Picard A; Armagnac C; Sissmann J; Mimran A
J Cardiovasc Pharmacol; 2001 Apr; 37(4):449-60. PubMed ID: 11300658
[TBL] [Abstract][Full Text] [Related]
7. Dose-ranging study of the angiotensin type I receptor antagonist losartan (DuP753/MK954), in salt-deplete normal man.
Doig JK; MacFadyen RJ; Sweet CS; Lees KR; Reid JL
J Cardiovasc Pharmacol; 1993 May; 21(5):732-8. PubMed ID: 7685442
[TBL] [Abstract][Full Text] [Related]
8. Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers.
Goldberg MR; Tanaka W; Barchowsky A; Bradstreet TE; McCrea J; Lo MW; McWilliams EJ; Bjornsson TD
Hypertension; 1993 May; 21(5):704-13. PubMed ID: 8491505
[TBL] [Abstract][Full Text] [Related]
9. Acute renal effects of AT1-receptor blockade after exogenous angiotensin II infusion in healthy subjects.
Schmitt F; Martinez F; Brillet G; Nguyen-Khoa T; Brouard R; Sissmann J; Lacour B; Grunfeld JP
J Cardiovasc Pharmacol; 1998 Feb; 31(2):314-21. PubMed ID: 9475275
[TBL] [Abstract][Full Text] [Related]
10. Dose-ranging study of the angiotensin II receptor antagonist irbesartan (SR 47436/BMS-186295) on blood pressure and neurohormonal effects in salt-deplete men.
McIntyre M; MacFadyen RJ; Meredith PA; Brouard R; Reid JL
J Cardiovasc Pharmacol; 1996 Jul; 28(1):101-6. PubMed ID: 8797143
[TBL] [Abstract][Full Text] [Related]
11. Human pharmacokinetic/pharmacodynamic profile of irbesartan: a new potent angiotensin II receptor antagonist.
Ruilope L
J Hypertens Suppl; 1997 Dec; 15(7):S15-20. PubMed ID: 9532516
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological differences among angiotensin II receptor antagonists.
Belz GG
Blood Press Suppl; 2001; 2():13-8. PubMed ID: 11465912
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
